ArticleFrontiers in bioengineering and biotechnology2026
Exploratory pilot study of minimally invasive therapy: laser ablation combined with acellular dermal matrix implantation for recurrent sacrococcygeal pilonidal disease.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Recurrent sacrococcygeal pilonidal disease (SPD) poses significant therapeutic challenges. Recently, minimally invasive techniques, notably laser ablation, have emerged as promising alternatives to conventional surgery. Concurrently, the application of acellular dermal matrix (ADM) has shown potential in facilitating wound healing and tissue regeneration. This small retrospective exploratory pilot study aims to evaluate the efficacy and safety of a combined therapeutic approach utilizing laser ablation and ADM implantation for the management of recurrent SPD. Methods: We retrospectively analyzed clinical data of our five patients who diagnosed with recurrent SPD between October 2023 and April 2024. All patients underwent laser ablation combined with ADM placement. Clinical outcomes, including healing rates, recurrence rates, and operative data, were recorded. Postoperative pain was quantified using the Visual Analog Scale (VAS), and the time to return to work and daily activities was documented. No sample size calculation was performed due to the exploratory nature of the study. Results: A total of five patients underwent laser ablation combined with ADM. The median time to return to work was 10 (9, 11) days, and complete wound healing was achieved in a median of 34 (30, 35) days. Patients experienced minimal postoperative pain. Over a median follow-up period of 7 (6-7) months, all patients were successfully cured without recurrence and satisfied with this surgery. Conclusion: Preliminary evidence suggests that laser ablation combined with ADM constitutes a feasible and promising minimally invasive strategy for recurrent SPD. This technique is associated with rapid wound healing, negligible pain, and the absence of recurrence in this cohort. This study is a small-sample retrospective pilot research with inherent limitations, and the findings warrant further verification by large-sample studies with medium and long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.